Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer
January 04, 2016 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune
December 21, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index
December 15, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies to Participate in Upcoming Investor Conferences
November 16, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity
November 09, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Announces Third Quarter 2015 Financial Results
November 05, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi
November 02, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers
October 07, 2015 08:01 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma
September 16, 2015 14:16 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma
September 14, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
NEW YORK, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...